Subtype
Cholangiocarcinoma
CI-CAN-00004932CCExplore in graph →
208 active trials3 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004932CCExplore in graph →
Clinical trials
758 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (106)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04645160 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT05712356 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors(BOLSTER) |
| completed |
| Phase 2 |
| 66 |
| Lisata Therapeutics, Inc.INDUSTRY |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06910670 | Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid | active not recruiting | N/A | 197 | Washington University School of MedicineOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07673341 | [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma | recruiting | Phase 2 | 22 | University of WashingtonOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841574 | HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC | recruiting | Phase 2 | 35 | Lianghe LuOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04145141 | National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | completed | — | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | recruiting | Phase 1 | 32 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06888063 | Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery(PUMP IV) | recruiting | Phase 2 | 40 | Erasmus Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836777 | Efficacy and Safety of MitoQ in Improving Cancer Cachexia | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07146646 | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer | recruiting | Phase 2 | 27 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 30 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06375915 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy(PM-CARE) | recruiting | Phase 2 | 33 | Francesco De CobelliOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02381561 | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04708067 | Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection(BRAVE) | recruiting | — | 1,000 | Imperial College LondonOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814586 | Prognostic Evaluation and Systematic Re-Assessment of Cholangiocarcinoma Therapy(Re-ACT) | not yet recruiting | — | 900 | Karolinska University HospitalOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07161869 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)(POELH-III) | recruiting | — | 250 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03212274 | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05039892 | Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 50 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06175845 | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma(ACTICCA-2) | recruiting | N/A | 130 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01915225 | Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | recruiting | — | 1,800 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | suspended | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07120295 | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | recruiting | Phase 4 | 75 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | recruiting | Phase 2 | 38 | Mehmet AkceOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma(CODAH) | not yet recruiting | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement(FOENIX-CCA4) | recruiting | Phase 2 | 120 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 1, 2026 | clinicaltrials |
| NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | not yet recruiting | Phase 1 | 20 | University of Illinois at ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05497531 | Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | recruiting | N/A | 15 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai 6th People's HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | not yet recruiting | Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06737692 | Effects of Aerobic and Resistance Exercise Training in Individuals With Cancer Cachexia(Exercise) | completed | N/A | 40 | Dokuz Eylul UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04510740 | Liver Cancer Registry Platform(JADE) | active not recruiting | — | 1,000 | iOMEDICO AGINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06923475 | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO) | recruiting | Phase 2 / Phase 3 | 150 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07043387 | Streamlining Radioembolization for CCC and Metastatic Liver Cancer(ISTAR-03) | recruiting | — | 60 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04891289 | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | recruiting | Phase 2 | 164 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | suspended | Phase 1 | 36 | University of Southern CaliforniaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06048133 | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | active not recruiting | Phase 2 | 33 | Nataliya UbohaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768085 | Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT | not yet recruiting | N/A | 40,000 | Shengjing HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07765433 | Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 / Phase 3 | 336 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Aug 14, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials